 |
| |
September 01, 2010:
Approval to start Phase IIa clinical trial with Lytixar™ (LTX-109)Oslo, Norway and Seoul, Korea, June 09, 2010:
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trialMay 20, 2010:
Update on the Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.May 20, 2010:
Approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trialMay 04, 2010:
General Assembly of Shareholders on 4th June 2010Tromsø, Norway, December 14, 2009:
Approvals from the Norwegian Medicines Agency and the Swedish Medical Products AgencySeptember 23, 2009:
Lytix Biopharma presented new data on antimicrobial drug LytixarTM (LTX-109) at ICAACAugust 19, 2009:
Lytix Biopharma announces today the start of dosing of its topical antimicrobial agent LytixarTM (LTX-109) in the Company’s first Phase I human volunteer trial.Tromsø, Norway, and Seoul, Korea, June 18, 2009:
Lytix Biopharma and KAEL–GemVax announce joint clinical trialJune 02, 2009:
North Murray AS has exercised warrant.March 24, 2009:
Lytix Biopharma has issued shares and a warrant directed at North Murray AS / Gert W. MuntheFebruary 26, 2009:
8 new job openings. We will expand our team of drug development professionals in support of the clinical development of two novel drugs. January 21, 2009:
Closure of a successful funding round to a total value of 73 million NOK (US$ 10.4 million), proceeds of which will fund the early-stage clinical development of two novel drugs. November 21, 2008:
Novel antimicrobial drug demonstrates ultra-rapid effectiveness against broad range of drug-resistant pathogensOctober 02, 2008:
Lytix' two Divisional Directors featured on the Norwegian Popular Science program "Schrödingers Katt".September 25, 2008:
Lytix Biopharma received the Norwegian bank DnB NORs Prize for innovation in Healthcare for its novel antimicrobial drug. Tromsø, August 11, 2008:
The Scandinavian-based drug development company Lytix Biopharma announced its intention to restructure the company into 2 divisional focus areas – infectious diseases and cancer.Tromsø, June 12, 2008:
Novel peptide demonstrates powerful tumour lysing properties Tromsø, May 28, 2008:
Lytix Establishes New Board of Directors
Tromsø, November 28, 2007:
Prospectus Private Placement MNOK 50Tromsø, September 20, 2007:
Novel antimicrobial shows increased efficacy versus gold standard Tromsø, October 23, 2006:
Synthetic AMPs (SAMPs™) offer ultra-broad spectrum action against highly resistant strains Tromsø, June 01, 2006:
Lytix Biopharma AS achieves promising results in animal models of cancer and has reached a significant milestone in its systemic anti-cancer drug development programme.Tromsø, April 30, 2006:
Lytix Biopharma AS has successfully closed a private placement of NOK 20.0 million with Norwegian investors. Tromsø, September 27, 2005:
Lytix Biopharma AS will attend BioPartnering Europe in London on 9th – 11th October 2005. The Company will be available for discussions with potential co-development or licensing partners during the meeting. Tromsø, August 27, 2005:
Lytix Biopharma AS announced today that it has successfully closed a funding round of NOK 5.0 million with local individuals and institutions, including local bank Sparebank1 Nord-Norge. The Company intends to use the funds in support of ongoing R&D activities in the two focus areas - antibiotic-resistant infections and cancer. Tromsø/Copenhagen, June 01, 2005:
Lytix Biopharma AS announced today that it has achieved a significant milestone in its anti-infectives drug development programme. Lead molecules selected for their activity against resistant bacteria, including methicillin-resistant Staphylococcus aureus, have been screened in an animal model of skin infection. Tromsø, February 08, 2005:
Lytix Biopharma AS has received funding from the Innovation and Technology Development Programme (NT-programmet) in support of the ongoing Lead Optimisation of the company’s topical antibiotic. Tromsø, October 20, 2004:
Lytix Biopharma AS announced today that it has successfully closed a funding round of NOK 3.84 million with local individuals and institutions. The Company intends to use the funds in support of ongoing R&D activities in the two focus areas - antibiotic-resistant infections and cancer. Oslo, August 11, 2004:
Lytix Biopharma AS has is now a part of Inkubator Tromsø, and has thus moved its corporate head quarter into the Incubator building at the research Park in Tromsø. Oslo, August 11, 2004:
Lytix Biopharma AS was awarded first place in the prestigious L.A. Enger Innovation Prize during the Oslo Business Summit 2004. In fierce competition with other Norwegian high-technology companies, the company was awarded first place and a prize worth NOK 50.000 for its innovative approach to the discovery of new drugs for the treatment of antibiotic-resistant infections and cancer. |
|
 September 01, 2010:
- Approval to start Phase IIa clinical trial with Lytixar™ (LTX-109)Oslo, Norway and Seoul, Korea, June 09, 2010:
- Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trialMay 20, 2010:
- Update on the Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.May 20, 2010:
- Approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial |
|||||
